Triple Negative Breast Cancer News and Research

RSS

Whole-genome sequencing could soon improve cancer survival rates

Cancer survival rates could improve soon with whole-genome sequencing, according to two studies published in the April 20, 2011, issue of the Journal of the American Medical Association that describe the first clinical applications of the high-tech process in patients with cancer.

20 Apr 2011

Breast cancer symposium to discuss on latest advances in research and treatment

The latest advances in both breast cancer treatment and research - including innovations in diagnostic, surgical, chemotherapy and radiation approaches - will be discussed Friday, April 8, 2011, at a breast cancer symposium at the Kimmel Cancer Center at Jefferson in Philadelphia.

7 Apr 2011

Scientists suggest genetic differences in breast tissue across ethnicities

Scientists from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are working on a series of genetic analyses that suggest the underlying differences among racial groups are present not just in tumors, but in normal tissue as well. Lisa Baumbach, Ph.D., associate research professor, and colleagues will present the full study results at the AACR 102nd Annual Meeting 2011, held here April 2-6.

5 Apr 2011

New study examines psychological, social challenges of women with breast cancer

When an aggressive form of breast cancer strikes a young woman, what kind of stress, anxiety and other psychological and social challenges does she face?

1 Apr 2011

AACR to honor UNC scientist with $181,000 grant for breast cancer research

The American Association for Cancer Research announced today that Carey Anders, MD, assistant professor of medicine and a member of UNC Lineberger Comprehensive Cancer Center will receive a Breast Cancer Research Foundation-AACR Grant for Translational Breast Cancer Research. The $181,000 grant will be presented at the organization's 102nd Annual Meeting, to be held in Orlando, Florida, April 2-6.

28 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.

2 Mar 2011

Study confirms risk of triple-negative breast cancer among obese, physically inactive women

New findings published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, confirm the risk of breast cancer among women who are obese and not physically active, and suggests additional mechanisms beyond estrogen.

1 Mar 2011

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

A new peptide developed by researchers in Temple University's College of Science and Technology has demonstrated efficacy against triple negative breast cancer.

1 Mar 2011

New study: Multiple full-term pregnancies may have higher risk of 'triple-negative' breast cancer

Full-term pregnancy has long been associated with a reduced risk of breast cancer, but a new study finds that the more times a woman gives birth, the higher her risk of "triple-negative" breast cancer, a relatively uncommon but particularly aggressive subtype of the disease.

24 Feb 2011

Genetic proof for anti-cancer properties of antioxidants and autophagy inhibitors

Researchers from Jefferson's Kimmel Cancer Center have genetic evidence suggesting the antioxidant drugs currently used to treat lung disease, malaria and even the common cold can also help prevent and treat cancers because they fight against mitochondrial oxidative stress-a culprit in driving tumor growth.

16 Feb 2011

Research on triple negative disease can benefit patients with breat cancer

Research to develop more effective treatments for triple negative breast cancer -- a difficult disease to cure -- could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.

1 Feb 2011

Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

Sanofi-aventis and its subsidiary, BiPar Sciences, today announced that a randomized Phase III trial evaluating iniparib (BSI-201) in patients with metastatic triple-negative breast cancer (mTNBC) did not meet the pre-specified criteria for significance for co-primary endpoints of overall survival and progression-free survival

28 Jan 2011

Study shows clinical benefits of iniparib in combination with standard chemotherapy for triple-negative breast cancer

A current New England Journal of Medicine study indicates that the use of the PARP inhibitor iniparib in combination with standard chemotherapy to treat metastatic triple-negative breast cancer offers a significant increase in clinical benefit, a measure of durable response or disease stabilization, as well as an increase in progression-free survival.

6 Jan 2011

Sanofi-aventis announces publication of positive BSI-201 phase II results for breast cancer

Sanofi-aventis and its wholly-owned subsidiary, BiPar Sciences, today announced that The New England Journal of Medicine published the final phase II data for the investigational drug iniparib demonstrating significant clinical benefit in women with metastatic triple negative breast cancer when iniparib was administered in combination with chemotherapy agents gemcitabine/carboplatin.

6 Jan 2011

Nektar reports positive results from NKTR-102 Phase 2 study in metastatic breast cancer at CTRC-AACR SABCS

Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in patients with metastatic breast cancer during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). NKTR-102, a novel investigational topoisomerase I inhibitor-polymer conjugate, is Nektar's lead oncology candidate and is being evaluated in multiple cancer indications.

14 Dec 2010

Syndax reports promising results from entinostat preclinical studies in breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer. The data are being presented as oral poster discussions at the San Antonio Breast Cancer Symposium December 8 through December 12 in San Antonio Texas.

13 Dec 2010

Scientists demonstrate triple-drug cocktail for triple negative breast cancer at AACR symposium

A gene target for drug resistance, a triple-drug cocktail for triple negative breast cancer, and patients' risk for carpal tunnel syndrome are among study highlights scheduled to be presented by Johns Hopkins Kimmel Cancer Center scientists during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

13 Dec 2010

Simple fingertip test may help evaluate risk for CTS in breast cancer patients

13 Dec 2010

HOXB7 gene raises tamoxifen resistance in women with early-stage breast cancer

13 Dec 2010

Triple Negative Breast Cancer News and Research

Whole-genome sequencing could soon improve cancer survival rates

Breast cancer symposium to discuss on latest advances in research and treatment

Scientists suggest genetic differences in breast tissue across ethnicities

New study examines psychological, social challenges of women with breast cancer

AACR to honor UNC scientist with $181,000 grant for breast cancer research

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Study confirms risk of triple-negative breast cancer among obese, physically inactive women

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

New study: Multiple full-term pregnancies may have higher risk of 'triple-negative' breast cancer

Genetic proof for anti-cancer properties of antioxidants and autophagy inhibitors

Research on triple negative disease can benefit patients with breat cancer

Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

Study shows clinical benefits of iniparib in combination with standard chemotherapy for triple-negative breast cancer

Sanofi-aventis announces publication of positive BSI-201 phase II results for breast cancer

Nektar reports positive results from NKTR-102 Phase 2 study in metastatic breast cancer at CTRC-AACR SABCS

Syndax reports promising results from entinostat preclinical studies in breast cancer

Scientists demonstrate triple-drug cocktail for triple negative breast cancer at AACR symposium

Simple fingertip test may help evaluate risk for CTS in breast cancer patients

HOXB7 gene raises tamoxifen resistance in women with early-stage breast cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News